Decreased beta-phenylethylamine in CSF in Parkinson's disease.
OBJECTIVE
To determine the concentrations of beta-phenylethylamine (PEA) in CSF in patients with Parkinson's disease, and to evaluate the relation between concentration of PEA in CSF and severity of Parkinson's disease.


METHODS
Using gas chromatography-chemical ionisation mass spectrometry, CSF concentrations of PEA were measured in 23 patients with Parkinson's disease (mean age, 64.0 (SD 8.2) years), of whom three were at Hoehn and Yahr stage II, 11 were at stage III, and nine were at stage IV. Comparison was made with eight patients with neuropathy (mean age, 57.0 (SD 19.2) years) and 12 controls without neurological disease (mean age, 57.6 (SD 4.8) years).


RESULTS
Concentrations of PEA in CSF in Parkinson's disease were significantly lower (mean 205 (SD 131) pg/ml) than in patients with peripheral neuropathy (433 (SD 254) pg/ml) and controls (387 (SD 194) pg/ml). The concentrations of PEA in CSF correlated negatively with Hoehn and Yahr stage (P<0.01).


CONCLUSIONS
There are decreased CSF concentrations of PEA in patients with Parkinson's disease.
Zhou
G
G
First Department (Neurology) of Internal Medicine, Kurume University School of Medicine, Japan.
Shoji
H
H
Yamada
S
S
Matsuishi
T
T
D000368:Aged; D002849:Chromatography, Gas; D005260:Female; D006719:Homovanillic Acid / Q000134:cerebrospinal fluid; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use; D008297:Male; D013058:Mass Spectrometry; D008875:Middle Aged; D010300:Parkinson Disease / Q000134:cerebrospinal fluid* / Q000188:drug therapy; D010523:Peripheral Nervous System Diseases / Q000134:cerebrospinal fluid; D010627:Phenethylamines / Q000134:cerebrospinal fluid*; D011619:Psychotropic Drugs / Q000134:cerebrospinal fluid*; D012720:Severity of Illness Index
D010627:Phenethylamines; D011619:Psychotropic Drugs; C029261:phenethylamine; D007980:Levodopa; D006719:Homovanillic Acid